Phase II Study of Neoadjuvant Chemotherapy With Doxorubicin Followed by Docetaxel-Cisplatin in Locally Advanced Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00538525
Recruitment Status : Completed
First Posted : October 2, 2007
Last Update Posted : May 30, 2012
Information provided by (Responsible Party):
King Faisal Specialist Hospital & Research Center

Brief Summary:
Phase II study of neoadjuvant chemotherapy with Doxorubicin followed by Docetaxel-Cisplatin in locally advanced breast cancer

Condition or disease Intervention/treatment Phase
Breast Cancer Drug: Doxorubicin, Docetaxel, Cisplatin Not Applicable

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 10 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Study Start Date : September 2007
Actual Primary Completion Date : April 2008
Actual Study Completion Date : April 2008

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer

Arm Intervention/treatment
Active Comparator: Arm 1
Doxorubicin, Docetaxel, Cisplatin
Drug: Doxorubicin, Docetaxel, Cisplatin
Doxorubicin, Docetaxel, Cisplatin

Primary Outcome Measures :
  1. Effectiveness [ Time Frame: overall ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients with locally advanced breast cancer

Exclusion Criteria:

  • Patients with metastatic breast cancer

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00538525

Sponsors and Collaborators
King Faisal Specialist Hospital & Research Center
Principal Investigator: Adnan Ezzat, MD KFSH&RC, Riyadh, Saudi Arabia

Responsible Party: King Faisal Specialist Hospital & Research Center Identifier: NCT00538525     History of Changes
Other Study ID Numbers: RAC#2011-022
First Posted: October 2, 2007    Key Record Dates
Last Update Posted: May 30, 2012
Last Verified: May 2012

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases
Liposomal doxorubicin
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Antibiotics, Antineoplastic
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors